PCM
ACET icon

Penserra Capital Management’s Adicet Bio ACET Stock Holding History

Penserra Capital Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-46
Closed -$5K – 1345
2021
Q3 		$5K Buy
46
+1
+2% +$124 ﹤0.01% 1404
2021
Q2 		$7K Buy
45
+2
+5% +$407 ﹤0.01% 1292
2021
Q1 		$8K Buy
43
+15
+54% +$3.44K ﹤0.01% 1055
2020
Q4 		$6K Buy
28
+25
+833% +$5.12K ﹤0.01% 967
2020
Q3 		$0 Buy
+3
New +$759 ﹤0.01% 928

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Penserra Capital Management's ACET Position: Q4 2021 in Review

Penserra Capital Management sold out of Adicet Bio (ACET) in Q4 2021, closing a stake of 46 shares — an estimated $5K sold.

Penserra Capital Management first reported a position in ACET in Q3 2020 and held it in 5 quarters. The position peaked at $8K in Q1 2021. 81 funds tracked by Wall St. Rank hold ACET as of Q4 2021.

  • Penserra Capital Management reported no remaining Adicet Bio position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 46 Adicet Bio shares in Q4 2021, an estimated $5K.
  • Penserra Capital Management first reported a position in Adicet Bio in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Adicet Bio position peaked at $8K in Q1 2021.
  • 81 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.